Home Companies Catalysts Deep Dives
Lutathera lutetium Lu177 dotatate APPROVED
Drug Profile
ModalityRadioligand therapy
RouteIV
Therapy AreaOncology
Launch2018-01-26
US LOE2034-01-26
Peak Sales Est$800M
Formulations[{"id":"lutathera-iv","doses":"7.4 GBq (200 mCi)","route":"IV","setting":"INFUSION_CENTER","frequenc
Companies
NVS (ORIGINATOR)100%
Mechanism: SSTR-targeting
Expert: Somatostatin analog conjugated to Lu-177, targeting somatostatin receptors (SSTR2) overexpressed on NETs
Everyday: Targets receptors on neuroendocrine tumor cells to deliver radiation directly
Targets: ["SSTR"]
Revenue History
PeriodRevenue ($M)
2024$620M
2025$680M
Programs (1)
IndicationStageKey StudyRegional Status
GEP-NETsAPPROVEDNETTER-1[{"stage":"APPROVED","region":"US","approval_date":"2018-01-26"},{"stage":"APPRO
Notes
Lu-177 DOTATATE for NET. First radioligand therapy approved.
Data from Supabase · Updated 2026-03-24